Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Receivables: 2019-2025

Historic Receivables for Burning Rock Biotech (BNR) over the last 4 years, with Sep 2025 value amounting to $25.8 million.

  • Burning Rock Biotech's Receivables rose 8.85% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year increase of 164.19%. This contributed to the annual value of $29.0 million for FY2024, which is 9.55% up from last year.
  • As of Q3 2025, Burning Rock Biotech's Receivables stood at $25.8 million, which was down 83.81% from $159.5 million recorded in Q1 2025.
  • Burning Rock Biotech's Receivables' 5-year high stood at $159.5 million during Q1 2025, with a 5-year trough of $11.7 million in Q1 2021.
  • Its 3-year average for Receivables is $71.4 million, with a median of $27.7 million in 2023.
  • As far as peak fluctuations go, Burning Rock Biotech's Receivables skyrocketed by 850.85% in 2023, and later plummeted by 85.25% in 2024.
  • Burning Rock Biotech's Receivables (Quarterly) stood at $27.3 million in 2021, then increased by 3.49% to $28.2 million in 2022, then fell by 6.16% to $26.5 million in 2023, then increased by 9.55% to $29.0 million in 2024, then climbed by 8.85% to $25.8 million in 2025.
  • Its last three reported values are $25.8 million in Q3 2025, $159.5 million for Q1 2025, and $29.0 million during Q4 2024.